For purposes of this notice, the "presentation" that follows shall mean and include the slides that follow, any oral presentation of the slides by members of management of Immunome, Inc. ("Immunome") or any person on its behalf, any question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. References to "we," "our," and "us" refers to Immunome and its subsidiaries. This presentation shall not cons ...

Core Insights - Immunome, Inc. (IMNM) shares increased by 6% to close at $9.3, driven by higher trading volume compared to typical sessions, contrasting with a 0.1% gain over the past four weeks [1][2] Company Performance - The rise in stock price is linked to growing investor optimism regarding the development of varegacestat, which is in late-stage clinical studies for treating desmoid tumors, alongside other early-stage cancer therapies [2] - The company is projected to report a quarterly loss of $0.52 per share, reflecting a year-over-year decline of 6.1%, with expected revenues of $2.47 million, an increase of 4.5% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 1.9% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Immunome is categorized under the Zacks Medical - Biomedical and Genetics industry, where Nurix Therapeutics, Inc. (NRIX) also operates, closing 2.2% lower at $11.39, with a 9.5% return over the past month [5] - Nurix Therapeutics has an unchanged consensus EPS estimate of -$0.72 for the upcoming report, representing a year-over-year change of -1.4% [6]

Core Insights - Immunome completed a $150 million financing round in January 2025, aimed at advancing its core pipeline into clinical translation [1] - The company announced the first patient dosing in the Phase I clinical trial of its ROR1-targeting ADC (antibody-drug conjugate) IM-1021 in March 2025 [1] - Immunome's core product pipeline, Varegacestat (AL102), has completed patient enrollment in the Phase III RINGSIDE trial, with topline data expected in the second half of 2025 [1] Company Overview - Immunome has raised a total of $598.9 million over 21 funding rounds since its establishment 17 years ago, indicating strong investor confidence [1][21] - The company specializes in targeted oncology and leverages rapid antibody screening and precise delivery technologies to address the limitations of traditional cancer treatments [1][2] Technology and Innovation - Immunome's competitive edge lies in its Memory B cell technology and Targeted Effector platform, which enhance antibody affinity and specificity while minimizing off-target damage [3][4] - The Memory B cell platform utilizes patient-derived memory B cells to discover antibodies that are naturally equipped to target tumor-specific antigens, particularly useful for resistant tumors [5] - The Targeted Effector platform allows for modular design to optimize drug delivery and efficacy, significantly improving the therapeutic index compared to traditional methods [6][7] Product Pipeline - Immunome's pipeline includes three clinical-stage products: Varegacestat (AL102), IM-1021 (ROR1 ADC), and IM-3050 (RLT) [8] - Varegacestat is an oral γ-secretase inhibitor targeting rare sarcomas, showing a 64% objective response rate in Phase II trials [9] - IM-1021 is designed to overcome resistance in solid tumors, utilizing a high drug-to-antibody ratio (DAR8) to enhance efficacy [11] - IM-3050 targets FAP-positive cancer-associated fibroblasts, demonstrating significant potential in overcoming the tumor microenvironment barriers [16][17] Financial Performance - In 2024, Immunome reported revenues of $9.04 million, reflecting a 35.5% year-over-year decline, although losses have narrowed compared to 2023 [23] - The financing structure is heavily weighted towards post-IPO funding, which poses dilution risks for existing shareholders [22]